Biosimilar drug market: the expected "fierce fight" is now "calm"

Biosimilars were once considered to be a new world full of competition and could significantly reduce the price of biopharmaceuticals with expired patents
.

But at least in the US market, this did not happen exactly as planned

Some companies have invested a lot of money in the development of biosimilar drugs, such as Novartis
.

Ronny Gal, an analyst at Bernstein, a US investment agency, said that although the results were not so dramatic, biosimilars had an overall easing effect on lowering prices

Ronnie Gal said in his quarterly study on the performance and prospects of biosimilars that although it may not seem obvious on the surface, biosimilars have always been a moderating force in reducing drug prices
.

Looking ahead, the market will enter a growth phase due to the launch of some blockbuster biosimilar products

"The winner here is the patient, who saves about $8.
8 billion a year
.

Now is the time to calm the argument that biosimilars cannot provide sufficient system savings-a better question is'Who benefits from it?'"

Although the US biosimilar market started slowly, in the past three quarters, the annualized value has reached approximately US$4 billion
.

In the entire market, the increase in trading volume was offset by a larger price drop

"This is because the latecomers of biosimilars continue to launch products, forcing the price of early entrants to drop, and the intensified competition from innovators.
All participants are now discounting prices in the competition
.

"

One example is the Remicade (infliximab) biosimilar drug Inflectra that Pfizer pioneered to market
.

When Pfizer launched Inflectra, there was a 15% discount on the Johnson & Johnson brand

Nevertheless, sales data show that Johnson & Johnson's brand Remicade is still the dominant force in the market
.

Remicade generated $3.

In addition to the Remicade biosimilar drug market war, Mylan launched Amgen Neulasta (Pegfilgrastim) biosimilars at a 33% discount in 2018, and once again demonstrated that some biosimilars offer substantial discounts.
Case
.

Looking ahead, with Roche’s macular degeneration drug Lucentis (ranibizuma, ranibizumab) and AbbVie’s multifunctional immunological blockbuster Humira (adalimumab) biosimilars will be launched in 2023.
Enstein believes that the US biosimilar drug market will experience moderate growth
.

As the popularity of the original research brand fades, the overall revenue of the biosimilar drug market will rebound, and the market is expected to enter another "10-year growth period

Regarding some of the big competitors in the field of biosimilar drugs, Pfizer's generic versions of Johnson & Johnson's Remicade and Roche Avastin (bevacizumab) will benefit in the short term
.
Amgen will decline in the short term, but the company plans to use Humira's biosimilars to gain an advantage in 2023
.
Bernstein believes that the stagnant Viatris (the merged company of Pfizer Pretron and Mylan) needs to change its strategy
.
As for Teva, it largely depends on its partnership with Alvotech.
The two companies reached a cooperation agreement on the production of biosimilar drugs in the US market last year
.

Although the adoption of biosimilars in the United States is still in its early stages, the adoption of biosimilars is on the rise
.
Roche Avastin's biosimilars have a particularly high penetration rate of 69%
.
In addition, according to IQVIA's data based on sales data at the end of June, Genentech Herceptin (Trastuzumab, trastuzumab) and Amgen Neupogen's biosimilar drugs also achieved market penetration rates of 57% and 62%, respectively
.

Roche Avastin's biosimilars have a particularly high penetration rate of 69%
.
In addition, according to IQVIA's data based on sales data at the end of June, Genentech Herceptin (Trastuzumab, trastuzumab) and Amgen Neupogen's biosimilar drugs also achieved market penetration rates of 57% and 62%, respectively
.

The Biosimilars Council estimates that by 2025, biosimilars could save the United States as much as 130 billion U.
S.
dollars
.

However, one of the main factors limiting the market size of biosimilars is the limited number of biosimilars on the market
.

According to the official website of the FDA, up to now, the agency has approved a total of 29 biosimilar drugs
.
After a record number of 10 approved in 2019, only 3 approved in 2020
.
No biosimilar drugs have been approved in the first half of this year
.
This also shows from the side that the development of biosimilar drugs in the US market may have slowly faded from the popularity of previous years
.

So far, the agency has approved 29 biosimilar drugs
.
After a record number of 10 approved in 2019, only 3 approved in 2020
.
No biosimilar drugs have been approved in the first half of this year
.

Secondly, it’s no wonder that in recent years, faced with increasingly fierce competition in the development of innovative drugs, especially in the field of biological products such as antibodies, which large multinational pharmaceutical company will put its main energy into the biosimilar drug market?

In China, according to the data published in the annual reports of various companies in the first half of 2021, most of the domestically approved biosimilar drug sales before 2021 also cover the tip of the iceberg in the market share of the original research drug
.